Valoración de la eficacia de una pauta más lenta y frecuente en la administración de hierro intravenoso en pacientes en hemodiálisis durante un año

One of the most common problems of chronic kidney disease (CKD) patients on haemodialysis (HD) is anaemia, usually treated with erythropoiesis-stimulating factors. This stimulation requires a greater availability of the body's iron (Fe) deposits.1 To reach the levels recommended by the guidelines (Ferritin between 200 and 400ng/ml - TSI between 30 and 40%), iron is administered intravenously (Fe IV)2. Administration guidelines vary according to the needs of patients, and it is usual to infuse 100mg Fe sucrose diluted in 100cc of physiological serum weekly, fortnightly or monthly3,4,5. This administration guideline is carried out in the last 45 minutes of the HD session, the ideal speed of perfusion of the dilution not being established. Therefore, we asked ourselves whether the speed of administration of intravenous iron could influence the efficacy of the treatment, as well as the presentation of adverse effects6. To this end, we set the following objectives: 1. To compare the efficacy between a slow pattern and a more frequent and ultra-slow pattern of Fe IV administration, with respect to the parameters of iron kinetics, as well as the erythropoietin and Fe contributions that were made. 2. Analyse whether fewer adverse effects are caused by intolerance to Fe IV administered in the ultra slow mode.